As Scale Up to Rx for 3M by 2005 Proceeds, Activist Groups Worldwide Begin to Lay Groundwork By Mark Harrington Educating Patients, Providers At the Barcelona AIDS conference this summer, TAG co-sponsored the first meeting of a new global coalition…
Consensus Statement in Opposition to Licensure of Remune As Monotherapy for HIV Infection in Thailand "Without a large burden for past research and development ... and based on a minimum gross profit of $75 per dose of Remune sold ..…
HIV Spread Threatens Decade's Tuberculosis Treatment/Prevention Success By Daniel Raymond New Challenges, Questions TB researchers and policy-makers from around the world gathered on 3-5 June 2002 in Washington, D.C., at the 4th World TB Congress (the 3rd was held ten…
Overwhelming Array of Variables Confounds Interpretation of Co-Infection Studies Answers Not Forthcoming Estimates of HCV prevalence among people with HIV in the United States range from 30% to 50%, with even higher rates among people infected through injection drug use…
Studies of PI-Resistant Virus Offer Tantalizing Possibilities for Immune Reconstitution "The 1,500 Copy Cut-Off" By Richard Jeffreys Every year, Keystone Symposia sponsor two parallel conferences on HIV pathogenesis and vaccines. The meetings take place at the Keystone Resort high in…
Scrapping Volunteer Model Meant Curtains for Activist Conscripts and Paved Way for TAG Ascendency By David Barr "Urgent Need to Teach, Train" Survey the leadership of major AIDS advocacy organizations, scan the mastheads of treatment publications, and chances are you'll…
By Richard Stern This e-mail was posted to the Health GAP Mailing List on March 29. It was a breath of fresh air to read Mark's piece ("Comments on Problems in the Current Draft World Health Organization (WHO) Antiretroviral Treatment…
HIV-Specific CD4 Cell, Holy Grail of Immune Control, Is Hunted Down in Paris Laboratory By Richard Jefferys "An Antibody Called IgG2" It's been five years since Bruce Walker and his Harvard colleagues first proposed the key role of CD4 T…
Merck's HIV Vaccine Program In a rapid-fire half-hour plenary session, Merck's head of HIV vaccine research Emilio Emini reviewed the company's development program and unveiled the first human immunogenicity data from phase I trials of their DNA and adenovirus type…
Activist Corpses Borne in Protest, Furtive Legislative Coups, and the Devastation That Was Berlin By Mark Harrington "We're Scientists Not Alchemists" Unlike clinical research in AIDS, basic research has not had a powerful constituency to advocate on its behalf. The…